Literature DB >> 12441037

Treatment and management of Helicobacter pylori infection.

Mae F Go1.   

Abstract

Clinical and basic mechanisms of interaction between Helicobacter pylori and its host have been the subject of numerous publications in the past year. Two additional proton pump inhibitors (PPIs), esomeprazole and rabeprazole, have shown effectiveness in H. pylori eradication when combined with amoxicillin and clarithromycin, and esomeprazole has demonstrated its effectiveness with only one daily dose. Other important recent developments worldwide include evidence-based treatment guidelines established at a European consensus meeting, improved accuracy in the urea breath test and the stool antigen test, new recommendations for second-line therapy, and a greater understanding of antimicrobial resistance in treatment failure. In addition, new studies have confirmed that H. pylori infection and use of nonsteroidal anti-inflammatory drugs or aspirin are the major causes of peptic ulcer disease and ulcer bleeding. This paper reviews the results of these studies and their implications for future research.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12441037     DOI: 10.1007/s11894-002-0023-1

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  26 in total

1.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori.

Authors:  B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).

Authors:  Gerhard Treiber; Joachim Wittig; Susanne Ammon; Siegfried Walker; Leen-Jan van Doorn; Ulrich Klotz
Journal:  Arch Intern Med       Date:  2002-01-28

3.  Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.

Authors:  Francis K L Chan; K F To; Justin C Y Wu; M Y Yung; W K Leung; Timothy Kwok; Y Hui; Henry L Y Chan; Cynthia S Y Chan; Elsie Hui; Jean Woo; Joseph J Y Sung
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

4.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

5.  Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials.

Authors:  L Laine; M B Fennerty; M Osato; J Sugg; L Suchower; P Probst; J G Levine
Journal:  Am J Gastroenterol       Date:  2000-12       Impact factor: 10.864

6.  Accuracy of stool antigen test in posteradication assessment of Helicobacter pylori infection.

Authors:  G Manes; A Balzano; G Iaquinto; C Ricci; M M Piccirillo; N Giardullo; A Todisco; M Lioniello; D Vaira
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

7.  Does Helicobacter pylori eradication reduce the long-term requirements for acid suppressants in patients with a history of peptic ulcer disease in general practice? Results from a four-year longitudinal study.

Authors:  Z Khan; P Nair; C O'Shea; N Spiers; R J Playford; A C Wicks
Journal:  Scand J Gastroenterol       Date:  2002-02       Impact factor: 2.423

8.  Outcomes of initial noninvasive Helicobacter pylori testing in U.S. primary care patients with uninvestigated dyspepsia.

Authors:  U Ladabaum; A M Fendrick; J M Scheiman
Journal:  Am J Gastroenterol       Date:  2001-07       Impact factor: 10.864

9.  Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.

Authors:  S D Georgopoulos; S D Ladas; S Karatapanis; K Triantafyllou; C Spiliadi; A Mentis; V Artikis; S A Raptis
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

10.  The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia.

Authors:  A Kokkola; P Sipponen; H Rautelin; M Härkönen; T U Kosunen; R Haapiainen; P Puolakkainen
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

View more
  2 in total

1.  Utility of the Nonabsorbed (<0.4%) Antibiotic Rifaximin in Gastroenterology and Hepatology.

Authors:  Chinyu G Su; Faten Aberra; Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

2.  Laboratory diagnosis and susceptibility profile of Helicobacter pylori infection in the Philippines.

Authors:  Raul V Destura; Eternity D Labio; Leah J Barrett; Cirle S Alcantara; Venancio I Gloria; Ma Lourdes O Daez; Richard L Guerrant
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-11-16       Impact factor: 3.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.